Helen I. Torley

2017

In 2017, Helen I. Torley earned a total compensation of $5.2M as President and Chief Executive Officer at Halozyme Therapeutics, a 7% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$699,115
Option Awards$1,900,003
Salary$671,000
Stock Awards$1,900,011
Other$10,422
Total$5,180,551

Torley received $1.9M in stock awards, accounting for 37% of the total pay in 2017.

Torley also received $699.1K in non-equity incentive plan, $1.9M in option awards, $671K in salary and $10.4K in other compensation.

Rankings

In 2017, Helen I. Torley's compensation ranked 1,795th out of 14,666 executives tracked by ExecPay. In other words, Torley earned more than 87.8% of executives.

ClassificationRankingPercentile
All
1,795
out of 14,666
88th
Division
Manufacturing
598
out of 5,768
90th
Major group
Chemicals And Allied Products
158
out of 2,074
92nd
Industry group
Drugs
114
out of 1,730
93rd
Industry
Biological Products, Except Diagnostic Substances
24
out of 316
92nd
Source: SEC filing on March 22, 2018.

Torley's colleagues

We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2017.

2017

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

2017

Harry Leonhardt

Halozyme Therapeutics

General Counsel

2017

Athena Countouriotis

Halozyme Therapeutics

Chief Medical Officer

2017

Mark Gergen

Halozyme Therapeutics

Chief Operating Officer

News

You may also like